ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Cipla licenses HIV drugs to Russia

by Jean-François Tremblay
June 27, 2016 | APPEARED IN VOLUME 94, ISSUE 26

India’s Cipla has signed a memorandum of understanding with the Russian firm National Immunobiological Co. (Nacimbio) concerning the use of Cipla technology for Russian manufacturing of antiviral drugs to treat HIV and hepatitis C. Russia currently does not produce the treatments. Investment on the project will approach $45 million, Nacimbio says. Cipla is one of the world’s largest producers of HIV drugs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment